OnCo
technologiesTechnologyPreclinical

DNA origami nanorobots

Folded DNA machines that open only when they touch a tumour, releasing a payload or clotting the tumour's blood supply.

DNA strands can be folded into nanoscale containers whose lids are aptamer locks that open on binding a tumour marker such as nucleolin. The best-known demonstration delivered thrombin into tumour vasculature in mice, causing intravascular thrombosis and tumour necrosis; a 2024 Karolinska design displayed death-receptor ligands only at tumour pH. Nothing in this class has entered human trials, and nuclease stability and manufacturing scale remain open questions.

Generic schematic · not to scale · placeholder for the drug discovery front
Guide RNA library · Knockout → dependency

How it works

Scaffolded DNA origami forms a hollow structure held shut by aptamer locks; binding the trigger opens the structure and exposes the payload only where the trigger is present.

Strengths
  • Logic-gated release confines activity to the tumour
  • Nanometre control of payload spacing
  • Materials are non-immunogenic in principle
Limitations
  • Preclinical only
  • Nuclease degradation and rapid clearance
  • Thrombosis-based designs carry obvious systemic risk
  • Manufacturing cost at clinical scale

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"DNA origami nanorobots" OR ABSTRACT:"DNA origami nanorobots") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DNA origami nanorobots, not a curated reading list.

Connected

5top